Genzyme/Sanofi-Aventis
On February 16 2011, Genzyme Corporation (Nasdaq: GENZ) confirmed a definitive agreement to be acquired by Sanofi-aventis (NYSE: SNY) for $74.00 per share in cash, or approximately $20.1 billion, plus one Contingent Value Right.
The Contingent Value Right entitling the holder to receive additional cash payments if specified milestones related to Lemtrada™ are achieved over time or a milestone related to production volumes in 2011 for Cerezyme® and Fabrazyme® is achieved. The CVR will be publicly traded.
The transaction is expected to close early in the second quarter of 2011.
Evercore Partners and J.P. Morgan served as sanofi-aventis' lead financial advisors on the transaction, and Weil, Gotshal & Manges LLP served as its legal counsel. Credit Suisse and Goldman Sachs served as financial advisors to Genzyme. Ropes & Gray LLP served as Genzyme's legal counsel, while Wachtell, Lipton, Rosen & Katz served as legal counsel to Genzyme's independent directors.
The Contingent Value Right entitling the holder to receive additional cash payments if specified milestones related to Lemtrada™ are achieved over time or a milestone related to production volumes in 2011 for Cerezyme® and Fabrazyme® is achieved. The CVR will be publicly traded.
The transaction is expected to close early in the second quarter of 2011.
Evercore Partners and J.P. Morgan served as sanofi-aventis' lead financial advisors on the transaction, and Weil, Gotshal & Manges LLP served as its legal counsel. Credit Suisse and Goldman Sachs served as financial advisors to Genzyme. Ropes & Gray LLP served as Genzyme's legal counsel, while Wachtell, Lipton, Rosen & Katz served as legal counsel to Genzyme's independent directors.
Genzyme Announces Successful Phase III Results for Alemtuzumab (LEMTRADA(TM*)) in Multiple Sclerosis
View Older Stories
-
Sanofi: Net sales up 10.1% and Business net income(1) up 4.1% at CER(2)
-
Sanofi Appoints David Meeker Chief Executive Officer of Genzyme
-
Alemtuzumab (Lemtrada™*) Significantly Reduces Relapses in Multiple Sclerosis vs Interferon Beta-1a in a Phase III Study
-
Global Pharmaceuticals: Global Therapeutic Conference 2011: Focus on Real-World Medicine
-
BlackRock (BLK) Replacing Genzyme (GENZ) in S&P 500
-
Canaccord Genuity Morning Coffee on Merck & Co. (MRK) and Sanofi-Aventis (SNY): So Long, Farewell, Au Revoir
-
Genzyme (GENZ) Board Unanimously Recommends Shareholders Approves Sanofi-Aventis (SNY)
-
Top 10 News Items 2/14-2/18: NYSE Euronext/Deutsche Boerse Announces Definitive Agreement, Sanofi, Genzyme Finally Approve Deal, Stocks Continue Higher, Up 28% Since Sept.
-
Jefferies Cuts Estimate & Raises Price Target on BioMarin Pharmaceutical (BMRN), Maintains Buy Rating
-
Canaccord Genuity Morning Coffee on Sanofi-Aventis (SNY) and Genzyme (GENZ): An Extra $5 Will Help The Medicine Go Down
-
Jefferies Downgrades Genzyme (GENZ) to Hold, Lowers EPS Estimates For FY11 & FY12
-
Morgan Joseph Downgrades Genzyme (GENZ) to Hold; To be Acquired for $74 Plus CVRs
-
Notable ETF Movers of the Day 02/16: (XRT) (USO) (TAN) Higher; (UNG) (VXX) (UUP) Lower
-
Notable Mergers and Acquisitions of the Day 02/16: GENZ/SNY, BEE, ARG/APD
-
Pre-Open Movers 2/16: (FDO) (VCLK) (DELL) Higher; (TNGN) (DSCO) (OMX) Lower
-
Genzyme (GENZ) Agrees To Be Acquired by Sanofi-aventis (SNY) for $20.1 Billion
-
Genzyme (GENZ) Reportedly Acquired by Sanofi-Aventis for $19.2B
-
Genzyme (GENZ) Jumps On Reports Deal Reached at $74/Share Plus Rights
-
Genzyme Corp. (GENZ) sees upside on news Sanofi-Aventis (SNY) deal could be announced soon
-
Goldman Sachs (GS) Has 6.8% Stake in Genzyme (GENZ, SNY)
-
Genzyme (GENZ) Stock Volatile With Pushing and Pulling In Sanofi Deal
-
Genzyme (GENZ) Valued at $20B by Sanofi Aventis; Deal Could Happen Within a Week
-
Genzyme (GENZ) Dips On Sanofi Headlines
-
Sanofi (SNY) talks said to value Genzyme (GENZ) at $76-$77/share with CVR fee -Bloomberg
-
Genzyme (GENZ) Will Allow Sanofi-Aventis To Conduct Due Diligence
-
This Hedge Fund Guru Profited Big-Time From the Buyout of Genoptix (GXDX), See What Other Targets He Is Buying
-
Sanofi-aventis (SNY) Tenders 0.4% of Genzyme (GENZ); Extends Deadline
-
Barclays Maintains an 'Equalweight' on Genzyme (GENZ); Slightly Weaker Results, Focus Remains on Sanofi Process
-
Genzyme (GENZ) Shares Rise as Sanofi's (SNY) Proposed Bid Wins EU Antitrust Approval
-
Genzyme (GENZ) Says Talks with Sanofi-Aventis (SNY) Continuing
-
Genzyme (GENZ) Reportedly Open to Price In Sanofi (SNY) Takeover Battle
-
Takeover Target Genzyme (GENZ) Has Meeting at 1PM ET
-
Genzyme (GENZ) Board Reiterates Position Following sanofi (SNY) $69/Share Tender Results
-
Ticonderoga Maintains a 'Neutral' on Evercore Partners (EVR); Dynegy Breakdown Highlights "Key Deal" Risk for EVR
-
Genzyme (GENZ) Chief Termeer Affirms $69/Share Bid Offers No Starting Point for Discussions (SNY)
-
Canaccord Genuity Maintains a 'Buy' on Amicus Therapeutics (FOLD); Rolling Out New Amigal Trials With GSK's Support
-
Sanofi-aventis (SNY) Seeks Clarification from Genzyme (GENZ) Over Potential Board Actions
-
sanofi-aventis (SNY) Expands Presence in China with $520.6M Acquisition of BMP Sunstone (BJGP)
-
Genzyme (GENZ) Confirms Issues Discussed in Presentation This Morning: $89/Share Estimate, Q4, FY11 Outlook
-
Genzyme (GENZ) Thinks its Worth $89/Share Based on Strong FY11 EPS View
-
Genzyme Corp. (GENZ) To Hold First Analyst and Investor Meeting October 22
-
Notable Mergers and Acquisitions of the Day 10/08: ALEX, GENZ/SNY
-
Genzyme's (GENZ) Board Unanimously Rejects Sanofi (SNY) Bid; Calls Offer 'Inadequate'
-
Genzyme's (GENZ) Board Allowing Management, Advisors to Look at Alternatives to Sanofi's Hostile Bid -WSJ
-
Sanofi's Pursuit of Genzyme (GENZ) Gets 'Hostile'; Higher Bid Seen
-
Notable Mergers and Acquisitions of the Day 10/04: SNY/GENZ, MSCC/ATCL, DDMX, BXP
-
Genzyme's (GENZ) Board Urges Shareholders Take No Action on Sanofi (SNY) Bid
-
Sanofi-aventis (SNY) Commences $18.5B Tender Offer for Genzyme Corp. (GENZ)
-
Raised Bid for Genzyme (GENZ) Could Be Coming as Sanofi (SNY) Scrounging for More Financing
-
Deutsche Bank Maintains a 'Hold' on Genzyme (GENZ); Genetics Sale-More Upside if Diagnostics Sold
